LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Volatile Breath Compounds Associated with Laryngeal Carcinomas

By LabMedica International staff writers
Posted on 06 May 2014
Print article
Image: Exhaling into a tedlar bag for volatile organic compound analysis (Photo courtesy of the Information and Scientific News Service (SINC).
Image: Exhaling into a tedlar bag for volatile organic compound analysis (Photo courtesy of the Information and Scientific News Service (SINC).
Exhaled breath contains thousands of gaseous volatile organic compounds (VOCs) that may be used as noninvasive markers of head and neck epidermoid cancer.

The technique of solid phase microextraction (SPME) may be useful for the analysis of exhaled air and it is one of the methods used to concentrate volatile organic compounds emitted by different sources.

Scientists at the Rey Juan Carlos University (Madrid, Spain) and the Foundation Hospital (Alcorcón, Spain) compared the volatile substances exhaled by 11 people with cancer of larynx in various phases of the disease, with those of another 20 healthy people, half of whom were smokers. The participants exhaled breath into tedlar bags after fasting for at least eight hours so there was no leftover food or drink on their breath.

The samples were then analyzed with solid phase microextraction, gas chromatography and mass spectrometry equipment (Agilent [Varian inc.], Palo Alto, CA, USA) which enable very small amounts of a substance to be separated and identified. The concentrations are around or slightly above the equipment's detection limits, 40 ng/mL, which is equivalent to 40 ppb (parts per billion).

The investigators found that that the air exhaled by the more seriously ill patients, in a stage called T3, contains different concentrations of seven compounds compared with the levels of healthy people or even those with a less developed tumor (T1). Specifically, in the graphics of individuals with advanced cancer, the peaks that represent ethanol (C2H6O) and 2-butanone (C4H8O) are particularly significant. These two compounds therefore become potential markers of laryngeal carcinoma.

A total of 31 common VOCs in non-smokers have been determined, whereas smokers reach up to 45 VOCs, thus differentiating the two types of populations. The study also identified four markers in the exhaled breath that are typical of smokers, such as benzene and furfural. The four marker compounds that were found and related to cigarette smoking but absent in nonsmokers, and these were: cyclohexa-1,3,5-triene (benzene), fural-dehyde, 4-isobutyl-1-(1-hydroxyethyl)-benzene, and 2,3,5-trimethylhexane.

Rafael A.García, PhD, a professor of Chemical Engineering, and lead author of the study said, “At the moment it is still a preliminary study and a wider sample has to be obtained but it is a step in the right direction, an alternative with regard to identifying biomarkers, not only for this type of cancer but for other more prevalent and serious ones such as lung cancer, where early detection is key.” The study was published in the March 2014 issue of the journal Chromatographia.

Related Links:

Rey Juan Carlos University
Foundation Hospital
Agilent


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.